Search research articles
Contact Us
Filters
Showing results (71-80 of 679) with videos related to
Page
of 68
Sort By:
PPAR Research
|
September 5, 2008
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
Mark A Deeg, Meng H Tan
PPAR Research
|
January 30, 2007
PPARs and Bone Metabolism
Beata Lecka-Czernik
PPAR Research
|
January 30, 2007
Fine-Tuning Reception in the Bone: PPARgamma and Company
Z Elizabeth Floyd, Sanjin Zvonic, Mark E Nuttall, et al.
PPAR Research
|
January 30, 2007
Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha)
Eric S Tien, Daniel B Hannon, Jerry T Thompson, et al.
PPAR Research
|
June 29, 2007
Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2
Shouwei Han, Ying Zheng, Jesse Roman
PPAR Research
|
September 4, 2010
PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study
Hirokazu Takahashi, Kunihiro Hosono, Takashi Uchiyama, et al.
PPAR Research
|
July 9, 2010
Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors
Tengis S Pavlov, John D Imig, Alexander Staruschenko
PPAR Research
|
August 14, 2010
The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease
Teresa Coll, Emma Barroso, David Alvarez-Guardia, et al.
PPAR Research
|
September 18, 2010
Regulation of PPARγ Coactivator-1α Function and Expression in Muscle: Effect of Exercise
Giulia Uguccioni, Donna D'souza, David A Hood
PPAR Research
|
July 31, 2010
PPAR-alpha Contributes to the Anti-Inflammatory Activity of Verbascoside in a Model of Inflammatory Bowel Disease in Mice
Emanuela Esposito, Emanuela Mazzon, Irene Paterniti, et al.
Page
of 68
Search research articles
Search
Showing results (71-80 of 679) with videos related to
Sort By:
Page
of 68
PPAR Research
|
September 5, 2008
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
Mark A Deeg, Meng H Tan
PPAR Research
|
January 30, 2007
PPARs and Bone Metabolism
Beata Lecka-Czernik
PPAR Research
|
January 30, 2007
Fine-Tuning Reception in the Bone: PPARgamma and Company
Z Elizabeth Floyd, Sanjin Zvonic, Mark E Nuttall, et al.
PPAR Research
|
January 30, 2007
Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha)
Eric S Tien, Daniel B Hannon, Jerry T Thompson, et al.
PPAR Research
|
June 29, 2007
Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2
Shouwei Han, Ying Zheng, Jesse Roman
PPAR Research
|
September 4, 2010
PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study
Hirokazu Takahashi, Kunihiro Hosono, Takashi Uchiyama, et al.
PPAR Research
|
July 9, 2010
Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors
Tengis S Pavlov, John D Imig, Alexander Staruschenko
PPAR Research
|
August 14, 2010
The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease
Teresa Coll, Emma Barroso, David Alvarez-Guardia, et al.
PPAR Research
|
September 18, 2010
Regulation of PPARγ Coactivator-1α Function and Expression in Muscle: Effect of Exercise
Giulia Uguccioni, Donna D'souza, David A Hood
PPAR Research
|
July 31, 2010
PPAR-alpha Contributes to the Anti-Inflammatory Activity of Verbascoside in a Model of Inflammatory Bowel Disease in Mice
Emanuela Esposito, Emanuela Mazzon, Irene Paterniti, et al.
Page
of 68